2020). The 2-deoxy glucose and 3-bromopyruvate, both glycolytic inhibitors, block the secretion and further diffusion of inflammatory cytokines, significantly alleviating the symptoms of arthritis (Garcia-Carbonell et al. 2016; Wang et al. 2020). As an inhibitor of Janus kinase, tofacitinib can also effectively downregulate the expression of key glycolytic enzymes in RA FLS and treat RA through metabolic reprogramming (McGarry et al. 2018). This evidence concerns the gene HK1 and rheumatoid arthritis.